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Abstract
Objective: The uptake of 3¶-[18F]fluoro-3¶-deoxythymidine (FLT), a proliferation marker, was
measured before and during fractionated radiotherapy to evaluate the potential of FLT-positron
emission tomography (PET) imaging as an indicator of tumor response compared to 2¶-deoxy-
2¶-[18F]fluoro-D-glucose (FDG).
Materials and Methods: Nude mice bearing established human head and neck xenografts
(HNX-OE; nu/nu mice) were locally irradiated (three fractions/week; 22 Gy) using a 150-kVp
unit. Multiple FDG- and FLT-PET scans were acquired during treatment. Tumor volume was
determined regularly, and tissue was analyzed for biomarkers involved in tracer uptake.
Results: Both groups revealed a significant decline in tumor volume (PG0.01) compared to
untreated tumors. For FDG as well as for FLT, a significant decline in retention was observed at
day 4. For FLT, most significant decline in retention was observed at day 12; whereas, for FDG,
this was already noted at day 4. Maximum decline in tumor-to-nontumor ratios (T/NT) for FDG
and FLT was 42T18% and 49T16% (meanTSD), respectively. FLT uptake was higher then that of
FDG. For FLT, statistical significant correlations were found for both tumor volume at baseline
and at day 29 with T/NTand DT/NT. All tumors demonstrated expression of glucose transporter-1,
thymidine kinase-1, and hexokinase II. No differences were found for amount of tumor cells and
necrosis at the end of treatment.
Conclusion: This new experimental in vivo model supports the promise of using FLT-PET, as
with FDG-PET, to monitor response to external radiotherapy. This warrants further clinical
studies to compare these two tracers especially in cancers treated with radiotherapy.
Key words: FDG, FLT, PET, Radiotherapy, Response monitoring, Head and neck xenograft
model
Introduction
Head and neck cancer represents 5% of all malignanciesdiagnosed annually, and 990% of tumors are of the
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squamous cell type [1]. The overall 5-year survival rate for
patients with head and neck squamous cell carcinoma
(HNSCC) of 50% is among the lowest of the major cancer
types [2]. Traditional staging of HNSCC depends on site of
disease, size and extent of the primary tumor, cervical
lymph node involvement, and presence or absence of distant
metastasis [3]. Currently, surgery and radiotherapy are
treatments of choice for primary HNSCC, with chemother-
apy reserved for more widespread disease [4]. Because of
variations in biological behavior, tumors of the same stage
often respond differently to the same treatment. Therefore,
not only correct staging of HNSCC but also monitoring
response to treatment is essential.
Unlike computed tomography and magnetic resonance
imaging, which are anatomical imaging techniques, positron
emission tomography (PET) is a quantitative molecular
imaging modality that allows for noninvasive in vivo
imaging and quantification of biological processes, such as
metabolism, receptor density, cell proliferation, and uptake
of therapeutic agents. Consequently, PET is a valuable tool
for detecting and especially staging of various tumor types.
2¶-deoxy-2¶-[18F]fluoro-D-glucose (FDG), a glucose analog,
is the most commonly used PET tracer in oncology, with
diagnostic, staging, and response monitoring applications
[5, 6]. A disadvantage of FDG-PET is uptake in other
tissues with physiologically high glucose consumption, such
as brain, muscle, inflammatory tissue, macrophages, and
lymphocytes [7]. In addition, FDG is less suitable for
monitoring response after/during radiotherapy, as often
increased uptake is seen after radiation caused by inflam-
matory lesions and fibrosis [8Y11].
Therefore, other tracers have been developed, such as 3¶-
[18F]fluoro-3¶-deoxythymidine (FLT), which is considered to
be more specific for proliferation, another characteristic of
tumor cells [12Y14]. FLT is retained in proliferating tissues
after it is phosphorylated by cytosolic thymidine kinase-1
(TK-1), one of the key cytosolic enzymes in the synthesis of
DNA [15Y19]. In most species, no metabolites of FLT can be
demonstrated [12]; only in monkeys and humans glucuroni-
dation of FLT has been observed. Shields et al. [13] have
demonstrated that it is possible to image tumor cell
proliferation using FLT. In general, sensitivity of detecting
tumors by FLT is comparable to that with FDG [12, 20].
Detection of bone metastases is more difficult with FLT
because of high physiological uptake of FLT in proliferating
bone marrow cells. However, unlike FDG, FLT is able to
discriminate between tumor and inflammatory tissue [21].
Therefore, FLT might be a suitable marker for tumor
response monitoring, especially after radiation therapy.
In the present study, first radiosensitivity of the human
head and neck cancer xenograft HNX-OE [22, 23] was
investigated. Next, FDG and FLT uptake in tumors during
and after fractionated radiotherapy was investigated within
the context of monitoring response to therapy. In vivo tracer
uptake was correlated with efficacy of radiotherapy and
with biological features in excised tumors subsequently.
Materials and Methods
Animal Model
Both flanks of NMRI nu/nu mice (age, 8Y10 weeks; weight, 22Y28 g;
Harlan, Zeist, the Netherlands) were implanted subcutaneously with
small tissue pieces of the human HNSCC HNX-OE, as described
previously [24]. Mice were kept in sterile surroundings with
standardized light/dark cycle and access to food and water ad
libitum. Tumor size was determined by caliper measurements at
least twice a week using the formula Tvol ¼ lwh2 (l, length; w,
width; h, height of the tumor) [25, 26]. Treatment started at tumor
volumes between 50 and 150 mm3. After the experiment, mice were
sacrificed and tumor tissue was rapidly excised. Tumors were
excised at days 38 and 36 after start of treatment for the FDG and
FLT group, respectively. Mice from the control group were killed at
day 16. All animal experiments were carried out in accordance with
the Dutch Law on Animal Experimentation and the institutional
committee on animal experimentation.
Radiotherapy
Local external beam radiation was applied using a clinical X-ray
therapy unit (PANTAK Therapax SXT, 150 kV photon, filter
8 [0.2 Al+1.0 Cu]) at a dose rate of 206.6 Gy/min. For
homogeneous dose distributions, anteroposterior and posteroante-
rior external beam radiotherapy fields were used. Radiation was
performed under intraperitoneally anesthesia using a mixture of
Ketamine/xylazine (2/1; 1 ml/kg; i.p.).
Experimental Design
Radiosensitivity As radiosensitivity of the tumor line HNX-OE was
unknown, a maximum tolerated dose (MTD) finding study was
carried out first. MTD is defined as a weight loss of maximally 10%
in the group of mice, with a maximum of 15% per individual mouse.
The weight of the mice was measured three times a week. Tumor-
bearing nude mice were randomized into five groups of six mice
each. Xenografts were exposed locally to a single radiation dose of
10, 14, 18 or 22 Gy, while the fifth group was not irradiated (control
group). Tumors were measured three times a week, and growth
curves were established, relating mean volume over time to the
volume on the first day of irradiation. Antitumor activity was
expressed as tumor-to-control tumor volume ratio (T/C) in percent-
age to control. Increase in life span (ILS) was also calculated. ILS was
defined as the median life span of the treated group divided by the
median life span of the control group, using the day of transplantation
as day 0. The day of death was defined as the day at which mice were
taken off the experiment.
Differences in significance between the antitumor effects of a
particular treatment were determined by means of KaplanYMeier
analysis.
Production of PET Tracers
FLT was produced according to the method described by Machulla
et al. [27] with modifications. This procedure resulted in a good
manufacturing practice (GMP) compliant, pyrogen-free, sterile
production of FLT with a radiochemical purity 997% and an
average (TSD) yield of 1.5T0.5 GBq and a mean specific activity
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of 100.2 GBq/mmol. FDG was produced under GMP conditions for
human use by BV Cyclotron VU (Amsterdam, the Netherlands)
with a radiochemical purity of 997%.
PET Protocol
PET studies were performed with a double-LSO-layer High Resolu-
tion Research Tomograph (HRRT, CTI, Knoxville, TN), a dedicated
animal and human brain scanner with no interplane septa (3D) and
with depth-of-interaction information. This scanner combines high
uniform spatial resolution with high absolute sensitivity [28]. For
attenuation correction, a transmission scan using a single-photon
137-Cs transmission point source was acquired.
PET scans were acquired under inhalation anesthesia (mixture
of 5% isoflurane: 95% oxygen). Acquisitions started 30 min after
tracer injection. Data were acquired in list mode during 60 min and
rebinned retrospectively into a series of four sinograms of 15 min
duration. All data were normalized, corrected for attenuation, and
reconstructed (using OSEM3D) into a series of image volumes
with a cubical voxel size of 1.2 mm. Reconstructed resolution was
almost isotropic with 2.2 mm full width at half maximum in the
center of the field of view and 2.5 mm at 10 cm off-axis [28].
Response Monitoring Three groups, each of six tumor-bearing
mice, were followed over time. One group served as control and
the other two groups (FDG and FLT groups) were exposed to 22
Gy in six fractions over a 2-week treatment schedule. PET scans
were performed in these latter two groups before and during
radiotherapeutic treatment, according to the schedule depicted in
Table 1. Tracer dose was 5.0T0.8 and 3.7T0.9 MBq for FDG and
FLT, respectively.
PET Analysis
Three-dimensional (3-D) regions of interest (ROIs) were placed
semiautomatically using dedicated software [29]. The tumor hot
spot was interactively set in the plane where the tumor was best
visible (frames 30Y60 min), and ROIs were then set automatically
using a 3-D region-growing algorithm around the tumor area and
in a corresponding normal tissue next to the tumor area in all
planes where the tumor was found. Tumor ROIs were copied to
normal tissue to obtain normal tissue ROIs of comparable size and
shape. Activity was calculated in pixels with an intensity of 70%
compared to the most intense pixel. Reference ROIs were used for
T/NT ratio calculation.
T=NT ¼ Radioactivity Concentration inTumor MBq=ccð Þ
RadioactivityConcentration inNormalTissue MBq=ccð Þ
Immunohistochemistry
Immunohistochemistry was performed on 4-mm thick formalin-
fixed, paraffin-embedded or 5 mm of cryostat xenograft tissue
sections as described earlier [30, 31]. Tumors were all excised at
days 38 and 36 after start of treatment for the FDG and FLT group,
respectively. Mice from the control group were all killed at day 16.
Representative sections of tumors were quantitatively analyzed for
the percentage of tumor cells, p53 nuclear staining and Ki67
expression, as described previously [30]. An experienced pathol-
ogist (G. M.), blinded to all other data, assessed the immunohis-
tochemically stained slides on a multiheaded microscope in the
presence of one junior (J. T. F.) and one senior (C. F. M. M.)
researcher with experience in immunohistochemistry. The intensi-
ty of tumor cell cytoplasmic staining for vascular endothelial
growth factor (VEGF) and hexokinase (HK) isoforms I, II, and III
was graded as negative (j), weak (+), positive (2+), and strongly
positive (3+), ignoring nuclear staining, which was frequently
noted for all HKs. The numbers of cells with Glut-1 membrane
and/or cytoplasmic staining, the amount of microvessels and
CD68-positive macrophages, were semiquantitatively scored as
none (j), occasionally (+), moderately frequent (2+), or frequent
(3+).
Statistical Analysis
In the radiosensitivity study, treatment effects in each group were
examined using KaplanYMeier analysis (SPSS for Windows
11.0.1, SPSS, Chicago, IL) followed by a log-rank test.
In the response monitoring study, differences between control
and FDG and FLT groups were examined by repeated measures
analysis of variance followed by a least significant difference test.
Univariate logistic regression was performed to assess the relation
between tumor volume after radiotherapy and final PET values (T/
NT). For testing associations between FDG and FLT accumulation
(defined as low vs high) and biological markers (defined as
negative/weak vs positive expression), a Fisher_s exact test was
performed. Median values were used as cut-off levels. The
strength of association between ordinal variables was represented
by Spearman_s rank correlation.
Results
Radiosensitivity
To determine the radiosensitivity of human HNX-OE
xenografts, tumors were locally irradiated with escalating
doses of external beam radiation. Tumor growth in all
treatment groups was inhibited compared with that in the
control mice, in a dose-dependent way (Fig. 1). Tumor
regrowth started 9 and 23 days after start of treatment in the
Table 1. Schematic outline of response monitoring experiment
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
FDG group A.M. FDG RTH FDG FDG RTH FDG FDG
P.M. RTH RTH RTH RTH
FLT group A.M. FLT FLT FLT FLT
P.M. RTH RTH RTH RTH RTH RTH
RTH Radiotherapy fraction; FDG FDG PET scan; FLT FLT PET scan
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groups treated with 10 and 14 Gy and 18 and 22 Gy,
respectively. A summary of treatment effects is listed in
Table 2. All treated groups showed an ILS, and MTD was
found to be 22 Gy. Statistical analysis demonstrated a
significant difference (PG0.001) between treated and control
tumors. In addition, a significant difference was found
between the 10 and 14 Gy group and the 18 and 22 Gy
groups (PG0.007).
No significant difference was found between tumors
treated with doses of 18 and 22 Gy (P=0.379).
Response Monitoring
Tumor-bearing mice received a baseline PET scan (FDG or
FLT), and tumors were fractioned exposed to 22 Gy in total
(six fractions, three times a week). Mice followed the
schedule over 2 weeks, and results were compared with
tumor-bearing mice in the control group. The growth curve
of HNX-OE tumor xenografts in untreated and irradiated
mice is presented in Fig. 2. Statistical analysis demonstrated
a significant difference (PG0.001) between treated and
control tumors from day 9 in both FDG and FLT group.
No statistical significant difference was found between the
FDG and FLT groups. A significant decline in tumor
volume for FDG (n=12 tumors) and FLT (n=11 tumors)
groups was found (both PG0.01). For both groups, tumor
regrowth started after day 29.
During radiotherapy, the maximum decline in T/NT
measured for FDG and FLT was 42T18% (scan 3) and
49T16% (scan 4; meanTSD), respectively. At all time
points, FLT uptake was higher than that for FDG, but
FDG uptake showed less variation. For FLT, the decrease
seen in the first week was followed by a much larger
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Fig. 1. Tumor growth of HNX-OE xenografts relative to tumor volume at start of local radiotherapy.
Table 2. Treatment effects after radiotherapy of HNX-OE xenografts
Group 10 Gy 14 Gy 18 Gy 22 Gy
Irradiation dosea (Gy) 9.9T0.4 14.0T0.1 18.0T0.7 22.0T0.2
ILSb 188T99 336T127 420T112 413T192
T/Cc
Day 2 22T22 17T30 28T26 21T14
Day 6 50T13 48T23 58T12 48T13
Day 8 47T17 50T21 61T16 50T17
Day 10 50T11 57T30 68T20 56T19
Day 13 70T32 71T15 75T14 70T9
Day 15 77T10 82T17 88T7 82T8
Day 17 77T8 77T28 89T4 84T8
Day 20 81T22 81T19 94T4 91T4
aDose in gray (Gy, meanTSD)
bIncreased life span in percentage to control (meanTSD)
cTumor-to-control tumor volume ratio (T/C) in percentage to control (meanTSD)
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as for FLT, a significant decline in retention (relative T/NT
ratio) was observed at scan 2 (day 4). Next to this
observation, for FLT, the most significant decline in
retention (relative T/NT ratio) was observed at scan 4 (day
12), whereas for FDG, this was already noted from scan 2
(day 4). Table 3 summarizes the results from the statistical
analyses correlating T/NT and changes in T/NT (DT/NT) to
tumor volumes at baseline (Vbaseline) to exclude differences
in the initial situation and at day 29 (Vday29). For FDG, no
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Fig. 3. FDG and FLT accumulation in HNX-OE xenografts. a absolute T/NT, tumor-to-nontumor ratio; b relative T/NT, tumor-
to-nontumor ratio.
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and any of the T/NT values. In contrast, for FLT, statistical
significant correlations were found for both Vbaseline and
Vday29 with T/NT and DT/NT of scans 2 and 3. Statistical
significance disappeared with respect to scan 4 possibly
because of the 4-day period between the last radiotherapy
and scan 4. For FDG, only a significant correlation was
found between Vday29 and T/NT baseline. A predictive
effect of baseline tumor volume was not found.
Immunohistochemistry
Table 4 summarizes the immunohistochemical results for
irradiated tumors together with tumor cell density and
amount of necrosis. Notable findings for irradiated tumors
as compared to control tumors were high levels of Glut-1
expression (13 of 15 tumors), HK II (9 of 16 tumors), and
Ki-67 expression (12 of 13 tumors). Expression of VEGF,
HK I, HK III, and TK-1 expression was similar for control
tumors and irradiated tumors. The same was true for
number of tumor cells and necrosis. However, no statistical
significant correlation could be demonstrated between the
biomarkers at the end of treatment and FDG or FLT uptake.
Histological findings showed severe radiation damage in
tumors.
Discussion
In the present study, the PET tracers FDG and FLT were
studied as potential tools for monitoring response during
fractionated radiotherapy. In an animal model of head and
neck cancer, the predictive value of FDG and FLT uptake
for tumor response to radiotherapy was assessed. In
addition, tumor biology and radiosensitivity of these
xenografts were studied.
To the best of our knowledge, there has been no report on
the radiosensitivity of the human HNSCC HNX-OE xeno-
grafts. Knowledge of radiosensitivity is required to be able to
use this animal model for radiation studies. Milas et al. [32]
reported treatment of nu/nu mice bearing A431 tumor
xenografts, derived from human epidermoid carcinoma,
with a single dose of 18 Gy. Whether this dose equaled
MTD was not reported. In a study of Jackel et al. [33] with
hypopharynx carcinoma xenografts, radiation doses varied
between 15 and 30 Gy, leading to a temporarily decrease in
tumor volume. In the present model, using locally applied
increasing radiation doses, MTD for HNX-OE xenografts
was found to be 22 Gy with a concomitant large decrease in
tumor volume, indicating a valid head and neck cancer
animal model for radiation studies. Therefore, for further
experiments with the HNX-OE tumor line, radiotherapy
with a dose of 22 Gy was favored.
To study response monitoring in the HNX-OE xenograft
model, a protocol was designed mimicking conventional
clinical radiotherapy protocols, with the view of predicting
effects of radiotherapy as soon as possible. From FDG
studies, it is known that, in general, changes in FDG signal
appear before changes can be detected in tumor volume
[34]. For FLT, however, little is known. Based on the
radiosensitivity experiments, it was assumed that fraction-
ated radiotherapy with a total dose of 22 Gy would result in
an adequate radiation dose for determination of the time
course of FDG and FLT signals after radiotherapy under
conditions that are relevant clinically. Indeed, a significant
reduction in tumor volume was observed after this treat-
ment. Tumor growth curves in both FDG and FLT groups
Table 3. Correlation between T/NT and tumor volume at baseline and at day 29 for FDG (n=12) and FLT (n=11)
Tumor volume baseline (Vbaseline) Relative tumor volume day 29 (Vday29)
FDG FLT FDG FLT
T/NT baseline 0.32 0.67a j0.67a j0.62a
Delta T/NT 2 (scan 2Vbaseline) j0.32 j0.62a 0.57 0.65a
Delta T/NT 3 (scan 3Vbaseline) j0.48 j0.65a 0.41 0.70a
Delta T/NT 4 (scan 4Vbaseline) j0.01 j0.17 0.30 0.51
Delta T/NT 5 (scan 5Vbaseline) j0.10 0.14
aCorrelation is significant at the 0.05 level (two-tailed)
Table 4. Immunohistochemical results in HNX-OE tumor xenografts treated with radiotherapy as compared to control tumors
Groupa VEGF Glut-1 HK I HK II HK III Ki-67 (%) TK-1 Tumor (%) Necrosis (%)
FLT 6 j 6 j 6 j 6 6 6
FDG 6 j 6 j 6 j 6 6 6
VEGF Vascular endothelial growth factor, Glut-1 glucose transporter protein-1, HK hexokinase, Ki-67 proliferation marker, TK-1 thymidine kinase 1,
Tumor (%) percentage of tumor cells, Necrosis (%) percentage of necrosis, 6 same range as control; j higher than control
aMice from the control, FDG, and FLT group were killed, and all tumors were rapidly excised on days 16, 38, and 36, respectively
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followed a similar pattern over time. FLT uptake was,
however, higher then that of FDG, and both FDG and FLT
uptake showed rapid response to radiotherapy. The decrease
in FLT uptake as seen in the first week was followed by a
much larger decrease in the second week, which was not the
case for FDG uptake. For FDG as well as for FLT, a
significant decline in retention (relative T/NT ratio) was
observed at scan 2 (day 4). Next to this observation, for
FLT, the most significant decline in retention (relative T/NT
ratio) was observed at scan 4 (day 12); whereas for FDG,
this was already noted from scan 2 (day 4). Statistical
significance disappeared with respect to scan 4 possibly
because of the 4-day period between the last radiotherapy
and scan 4. In a study of Sugiyama et al. [35], C3H/He
mice, bearing SCCVII tumors (murine SCC), who received
a single dose of 20 Gy, showed a rapid response to
radiotherapy both with respect to FDG and FLT uptake in
line with the present results.
Several patient studies have demonstrated a significant
higher uptake of FDG than FLT in various cancer types [20,
36, 37]. In the present animal model, FDG accumulation in
HNX-OE tumor xenografts was relatively low compared to
similar animal studies of Zhuang et al. [11] and Dearling et
al. [38]. On the other hand, Humm et al. [39] reported that
FDG uptake in xenografts grown in rodents was usually low,
as most activity was observed in other tissues such as
bladder, liver, brain, and heart. Considerable variability in
FDG and FLT uptake was observed both before and after
radiotherapy. Differences in tumor architecture, like capillary
and tumor density and hypoxic and necrotic cell fractions,
might have contributed to this variability. In addition,
differences in response to radiotherapy might have led to a
variance in tracer uptake. Differences in inflammatory
reactions, which are conceivable, may alter FDG uptake [5,
8Y11]. However, no differences with respect to biomarkers,
possibly involved in tracer uptake, were seen between FDG
and FLT groups. Compared to the control group, high
levelsVthough not statistically significantVof glucose trans-
porter-1, HK II, and Ki67 expression were found at the end
of treatment in both FDG and FLT groups. This might
possibly implicate survival of cells with a more aggressive
phenotype after treatment. One has to bear in mind, however,
that control tumors in this study were excised 16 days after
start of the experimentsVas a result of tumor loadVcompared
to 36/38 days for the FDG and FLT groups.
With respect to FLT variability, irradiation effects on
TK-1 activity have been thought to alter FLT uptake [18,
40]. Temporary inhibition of this key enzyme after low dose
irradiation has been reported [41]. In a study of Wei et al.
[40], an increase in TK-1 activity was found 24 h after
irradiation. Therefore, the time between irradiation and PET
scan should be as long as possible to allow for recovery of
TK-1 from short-term irradiation effects. A period of 48Y72
h between radiotherapy and PET scans used in the present
study is, however, considered to be long enough to exclude
effects on TK-1.
Humm et al. [39] examined FDG uptake after radiother-
apy in rats and found no predictive effect. However, very
large variations were observed in starting size of the tumors
as well as in tumor growth patterns. Nonetheless, their data
did demonstrate a trend between decreasing total FDG
accumulation and decreasing tumor burden with an increase
in recurrences. In our study, to exclude differences in the
initial situation for both tracer groups and to analyze a
possible predictive tool, the relationship between tracer
uptake and baseline tumor volume was analyzed. A
predictive effect by PET tracer uptake on tumor volume
after radiotherapy has been found in the presented study:
tracer uptakeVexpressed as baseline T/NT valueVpredicted
tumor volume later on (high baseline uptake predicted small
tumors at day 29 [day of tumor regrowth]). A predictive
effect of baseline tumor volume itself was not found.
In conclusion, results from this new experimental in vivo
model support the promise of using FLT-PET, as with
FDG-PET, to monitor response to external radiotherapy.
This warrants further clinical studies to compare these two
tracers especially in cancers treated with radiotherapy.
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